$13.16
+2.41 (+22.42%)
PMN News16 articles
Intellia Therapeutics Surges 23% on Promising Phase 3 Data for CRISPR Therapy
Intellia Therapeutics shares surged 23% to $14.92 after Phase 3 data showed lonvo-z reduced hereditary angioedema attacks by up to 91% versus placebo, with FDA filing as the next catalyst.
J&J Stock Nears Record Highs on Promising Talvey Data
J&J shares rose 1.07% to $240.87 after new Talvey combination data showed up to 72% reduction in disease progression risk, bolstering the oncology pipeline.
Ford Stock Pulls Back as May Sales Slide and Recalls Mount, but Energy Unit Holds Promise
Ford shares fell 2.7% to $15.71 as May sales plunged 13.6% and fresh recalls hit, but premarket gains reflect investor focus on Ford Energy's 20 GWh battery storage deal with EDF.
Legend Biotech Surges 42% on Promising Early CAR-T Data
Legend Biotech shares surged 42% after early Phase 1 data showed all six high-dose patients with relapsed B-cell non-Hodgkin lymphoma responded to its in vivo CAR-T therapy, with five achieving complete responses.
Legend Biotech Surges on Promising Early In Vivo CAR-T Data
Legend Biotech shares soared over 35% after early Phase 1 data showed all six high-dose patients with relapsed/refractory B-cell NHL responded to its in vivo CAR-T drug LB2501, with five complete responses and no relapses as of April 1.
Revolution Medicines Stock Gains Pre-Market on Promising Pancreatic Cancer Data
Revolution Medicines shares gained 1.9% premarket after Phase 3 data showed its experimental pill daraxonrasib nearly doubled median survival in pancreatic cancer to 13.2 months versus 6.7 months for chemotherapy.
Akari Therapeutics Surges on Promising KRAS Cancer Data and $5.5M Financing
Akari Therapeutics shares surged over 100% in premarket trading after its lead drug candidate AKTX-101 showed positive preclinical results in KRAS-mutated pancreatic cancer models and the company announced a $5.5 million private placement.
Immunovant Shares Surge on Promising Arthritis Drug Data
Immunovant shares soared 35% after its experimental rheumatoid arthritis drug, IMVT-1402, demonstrated high response rates in a difficult-to-treat patient population, prompting a re-rating by Wall Street.
Relay Therapeutics Surges on Promising Vascular Anomaly Data
Relay Therapeutics shares surged 11.3% premarket after reporting a 60% volumetric response rate from its Phase 2 trial of zovegalisib for vascular anomalies, with no patient discontinuations due to adverse events.
Tonix Pharma Surges on Promising Lyme Antibody Data; Phase 2 Trial Eyed for 2027
Tonix Pharmaceuticals shares rose after new Phase 1 modeling data for its Lyme antibody TNX-4800 showed six-month protection with two doses. A Phase 2 trial is targeted for 2027.
D-Wave's Record Bookings Show Promise, Revenue Lag Remains Concern
D-Wave's Q1 bookings hit $33.4M, up 1,994%, driven by a $20M system sale. Revenue fell 81% to $2.9M, and net loss widened to $18.4M. Shares rose 6.47%.
Ernexa Therapeutics Surges 60% on Promising Ovarian Cancer Preclinical Data
Ernexa Therapeutics shares jumped about 60% after the company announced its ERNA-101 cell therapy plus PD-1 blockade eliminated tumors and achieved 100% long-term survival in preclinical ovarian cancer models.
Celcuity Surges 16% on Promising Breast Cancer Drug Data
Celcuity shares jumped 16% after its lead drug candidate, gedatolisib, met the primary endpoint in a Phase 3 breast cancer trial for PIK3CA-mutant tumors, setting the stage for a supplemental FDA filing.
Coinbase Shares Surge as Senate Compromise Revives Stablecoin Regulation Bill
Coinbase shares climbed Monday after a Senate compromise on stablecoin rewards revived the CLARITY Act, which had been stalled for months.
AbbVie's Early Obesity Drug Trial Shows Promising Weight Loss Results
AbbVie reported its amylin-based obesity candidate ABBV-295 led to significant weight reduction in an early study, with no serious safety issues observed. The data marks a strategic step for the company as it seeks growth beyond immunology.
JNJ Nears 52-Week Peak Amid Legal Win and Promising Heart Device Data
Johnson & Johnson shares approach a 52-week high after a New Jersey court disqualified a plaintiffs' firm from talc cases and the company released positive pilot data for its experimental atrial fibrillation platform.